Millions rely on Medicare, yet common misunderstandings about its coverage rules and costs can lead to significant financial shocks in retirement. We clarify three critical areas where assumptions often prove wrong.
Sonesta International Hotels concludes a sweeping multi-year renovation initiative, injecting modern amenities and design into properties from New York to Kaua'i, as the company sharpens its competitive edge in the hospitality sector.
Oracle shares slid in premarket trading after the company unveiled plans to raise up to $50 billion this year to fuel its cloud and AI expansion, prompting investor unease over its growing debt burden and the long-term payoff of the sector's spending spree.
Despite a strong three-year run, shares of Ollie's Bargain Outlet (OLLI) dipped this week, prompting investors to weigh its solid earnings growth against recent market performance.
Oracle announces plans to raise up to $50 billion in 2026 through debt and equity to massively expand its cloud data centers, aiming to meet surging demand from AI leaders like Nvidia, OpenAI, and xAI.
A wave of insider buying at 908 Devices Inc. has caught the market's attention, signaling potential optimism among those who know the company best. While not a guaranteed predictor, such coordinated activity often precedes significant corporate developments.
While investors chase AI and big tech, a niche biotech firm focused on rare genetic obesity disorders has quietly delivered staggering returns, with Wall Street seeing further 40% upside. Rhythm Pharmaceuticals' targeted approach and upcoming catalysts have analysts bullish, despite its relative anonymity.
Iranian authorities announced the arrest of four foreigners allegedly involved in last month's widespread unrest, seizing homemade explosives in the operation as the government continues to blame external actors for domestic turmoil.
BeOne Medicines extends its collaboration with quantitative systems pharmacology firm InSysBio, aiming to optimize clinical trial dosing and mitigate cytokine release syndrome risks across its broad portfolio of 15 novel oncology assets.
Under Armour faces a pivotal moment as a significant insider purchase coincides with a high-stakes legal loss and the exit of its Chief Product Officer, testing investor confidence in the embattled sportswear brand's turnaround strategy.
Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.
A deep dive into the conflicting signals from Church & Dwight's stock valuation. While a discounted cash flow model suggests a significant discount, its premium P/E ratio tells a different story, leaving investors to weigh pricing power against market expectations.
Shares of Empire State Realty Trust (ESRT) are trading at $6.63, presenting investors with a conundrum: a narrative suggesting undervaluation clashes with a premium price-to-earnings multiple. We examine the divergence and what it means for the iconic property owner.
A new valuation model suggests Eos Energy Enterprises' stock could be significantly undervalued, presenting a potential opportunity for investors amid a shifting energy policy landscape.
With a cash reserve that could last just over a year at its current burn rate, InflaRx faces a critical period to prove its clinical pipeline's value. While management has reined in spending, the company's financial strategy is now under the microscope.
Five years after its peak, Polkadot (DOT) trades at a staggering 97% discount from its all-time high. Once a top-tier crypto, it has now fallen outside the top 30. We examine whether its steep discount represents a hidden opportunity or a sign of a failed thesis in a market now dominated by Ethereum and Solana.
Despite a 35% monthly plunge, Hedera's HBAR shows signs of underlying buyer interest through key technical divergences. However, a critical shift in exchange flows threatens to delay any near-term price rebound, leaving the token at a pivotal juncture.
The rapid adoption of OpenClaw, an open-source autonomous AI agent platform, is moving beyond social media buzz to directly execute transactions on blockchain networks, prompting both excitement about efficiency and deep concerns over market stability and accountability.
Digital asset funds have recorded a second consecutive week of massive outflows, totaling $1.7 billion, as hawkish Fed signals and geopolitical tensions trigger a defensive shift. While Bitcoin and Ethereum led the retreat, tokenized precious metals emerged as a rare destination for new capital.
Ripple's Chief Technology Officer, David Schwartz, has expressed skepticism about XRP reaching prices of $50 or $100, triggering a debate within the community as the cryptocurrency's value drops significantly this week.
